E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/2/2005 in the Prospect News Biotech Daily.

Jefferies maintains Connetics hold

Connetics was maintained at hold by Jefferies and Co. Inc. analysts David Windley and Himanshu Rastogi, who lowered the price target to $15 from $17 after the company announced soft third-quarter results. Earnings per share of $0.39 beating Jefferies' estimate of $0.22, but the analysts said they consider Connetics' valuation to be near its bottom. Margin was under estimate at 17.9% and management increased guidance for research and development and operating expenses. Shares of the Palo Alto, Calif.-based pharmaceutical company were down $0.25, or 1.95%, at $12.60 on volume of 1,656,469 shares versus the three-month running average of 514,747 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.